Link A A, Kino T, Worth J A, McGuire J L, Crane M L, Chrousos G P, Wilder R L, Elenkov I J
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, MD 20892, USA.
J Immunol. 2000 Jan 1;164(1):436-42. doi: 10.4049/jimmunol.164.1.436.
Adenosine (ADO) exerts potent anti-inflammatory and immunosuppressive effects. In this paper we address the possibility that these effects are partly mediated by inhibition of the secretion of IL-12, a proinflammatory cytokine and a major inducer of Th1 responses. We demonstrate that 5'-N-ethylcarboxamidoadenosine (NECA), a nonspecific ADO analogue, and 2-p-(2-carbonyl-ethyl)phenylethylamino-5'-N-ethylcarboxamidoadenos ine (CGS-21680), a specific A2a receptor agonist, dose-dependently inhibited, in whole blood ex vivo and monocyte cultures, the production of human IL-12 induced by LPS and Stapholococcus aureus Cowan strain 1. However, the A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine and the A3 receptor agonists N6-Benzyl-NECA and 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-be ta-d -ribofuranuronamide expressed only weak inhibitory effects. On the other hand, NECA and CGS-21680 dose-dependently potentiated the production of IL-10. The differential effect of these drugs on monocyte IL-12 and IL-10 production implies that these effects are mediated by A2a receptor signaling rather than by intracellular toxicity of ADO analogue's metabolites. Moreover, CGS-21680 inhibited IL-12 production independently of endogenous IL-10 induction, because anti-IL-10 Abs failed to prevent its effect. The selective A2a antagonist 8-(3-Chlorostyryl) caffeine prevented the inhibitory effect of CGS-21680 on IL-12 production. The phosphodiesterase inhibitor Ro 20-1724 dose-dependently potentiated the inhibitory effect of CGS-21680 and, furthermore, Rp-cAMPS, a protein kinase A inhibitor, reversed the inhibitory effect of CGS-21680, implicating a cAMP/protein kinase A pathway in its action. Thus, ligand activation of A2a receptors simultaneously inhibits IL-12 and stimulates IL-10 production by human monocytes. Through this mechanism, ADO released in excess during inflammatory and ischemic conditions, or tissue injury, may contribute to selective suppression of Th1 responses and cellular immunity.
腺苷(ADO)具有强大的抗炎和免疫抑制作用。在本文中,我们探讨了这些作用部分是通过抑制白细胞介素-12(IL-12)的分泌来介导的可能性,IL-12是一种促炎细胞因子,也是Th1反应的主要诱导因子。我们证明,5'-N-乙基羧基酰胺腺苷(NECA),一种非特异性ADO类似物,以及2-对-(2-羰基-乙基)苯乙氨基-5'-N-乙基羧基酰胺腺苷(CGS-21680),一种特异性A2a受体激动剂,在体外全血和单核细胞培养中,剂量依赖性地抑制了由脂多糖(LPS)和金黄色葡萄球菌考恩1株诱导的人IL-12的产生。然而,A1受体激动剂2-氯-N6-环戊基腺苷以及A3受体激动剂N6-苄基-NECA和1-脱氧-1-[6-[[(3-碘苯基)甲基]氨基]-9H-嘌呤-9-基]-N-甲基-β-D-呋喃核糖酰胺仅表现出微弱的抑制作用。另一方面,NECA和CGS-21680剂量依赖性地增强了IL-10的产生。这些药物对单核细胞IL-12和IL-10产生的不同作用表明,这些作用是由A2a受体信号传导介导的,而不是由ADO类似物代谢产物的细胞内毒性介导的。此外,CGS-21680独立于内源性IL-10的诱导抑制IL-12的产生,因为抗IL-10抗体未能阻止其作用。选择性A2a拮抗剂8-(3-氯苯乙烯基)咖啡因阻止了CGS-21680对IL-12产生的抑制作用。磷酸二酯酶抑制剂Ro 20-1724剂量依赖性地增强了CGS-21680的抑制作用,此外,蛋白激酶A抑制剂Rp-cAMPS逆转了CGS-21680的抑制作用,表明其作用涉及cAMP/蛋白激酶A途径。因此,A2a受体的配体激活同时抑制IL-12并刺激人单核细胞产生IL-10。通过这种机制,在炎症、缺血状态或组织损伤期间过量释放的ADO可能有助于选择性抑制Th1反应和细胞免疫。